Clinical Trial

DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis

Staff July 22, 2022

Topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE...

Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

Staff July 22, 2022

Completed enrollment of Cohort 1 in ReSPECT-LM Phase 1/2a dose escalation trial of 186RNL for Leptomeningeal Metastases On track to...

Gritstone Establishes Credit Facility for Up to $80 Million with Hercules Capital and Silicon Valley Bank

Staff July 22, 2022

EMERYVILLE, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to...

Cytokinetics to Announce Second Quarter Results on August 4, 2022

Staff July 22, 2022

SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled...

Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022

Staff July 22, 2022

BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development,...

ReWalk Receives Court Approval for Share Repurchase Program

Staff July 21, 2022

MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, July 21, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (the...

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis

Staff July 21, 2022

SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics (NASDAQ: PLRX) announced today that PLN-74809, its oral,...

180 Life Sciences Corp. Announces Closing of $6.5 Million Registered Direct Offering

Staff July 21, 2022

PALO ALTO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the...

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Staff July 21, 2022

HAMPTON, N.J., July 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been...

Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update

Staff July 21, 2022

WARMINSTER, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive...

Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ / HER2- Metastatic Breast Cancer

Staff July 21, 2022

SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that...

BridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic Diseases

Staff July 21, 2022

PALO ALTO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic...

BridgeBio Pharma Announces Founding Affiliation with Bakar Labs, Incubator at UC Berkeley’s Bakar BioEnginuity Hub

Staff July 21, 2022

PALO ALTO, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic...

Adamis Pharmaceuticals Issues Letter to Stockholders

Staff July 21, 2022

SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty...

Amryt to Report Q2 2022 Results on August 4, 2022

Staff July 21, 2022

DUBLIN, Ireland, and Boston MA, July 21, 2022, Amryt (Nasdaq: AMYT) a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing...

Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform

Staff July 21, 2022

European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural...

Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital

Staff July 21, 2022

DEVON, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid...

Skye Bioscience Selects NextPharma as Phase 2 Contract Drug Manufacturer

Staff July 21, 2022

Skye advances Phase 2 clinical development plans alongside Phase 1 clinical development San Diego, California, July 21, 2022 (GLOBE NEWSWIRE) -- Skye Bioscience,...

Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma

Staff July 21, 2022

--6th Orphan Drug Designation granted to toripalimab in the US and EU SHANGHAI, China, July 21, 2022 (GLOBE NEWSWIRE) --...

New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B

Staff July 21, 2022

Treatment with FLT180a led to durable expression of coagulation factor IX (FIX) and strong decreases in both bleeding rates and...

Clinical Trial

DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis

Plus Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

Gritstone Establishes Credit Facility for Up to $80 Million with Hercules Capital and Silicon Valley Bank

Cytokinetics to Announce Second Quarter Results on August 4, 2022

Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022

ReWalk Receives Court Approval for Share Repurchase Program

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis

180 Life Sciences Corp. Announces Closing of $6.5 Million Registered Direct Offering

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria

Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update

Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ / HER2- Metastatic Breast Cancer

BridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic Diseases

BridgeBio Pharma Announces Founding Affiliation with Bakar Labs, Incubator at UC Berkeley’s Bakar BioEnginuity Hub

Adamis Pharmaceuticals Issues Letter to Stockholders

Amryt to Report Q2 2022 Results on August 4, 2022

Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform

Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital

Skye Bioscience Selects NextPharma as Phase 2 Contract Drug Manufacturer

Junshi Biosciences Receives Orphan Medicinal Product Designation from the European Committee for Toripalimab in Treatment of Nasopharyngeal Carcinoma

New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B

Glow Lifetech Delivers 480% Quarter-Over-Quarter Revenue Growth with Industry-Leading 70% Gross Margin

ActivTrak Ranks No. 2335 on the 2024 Inc. 5000

Corewell Health and Gift of Life Michigan Launch InVita Healthcare Technologies’ iReferral in Nation’s Largest Launch to-date, Streamlining Critical Donor Referral Process

Quantiphi Strengthens AI Drug Discovery, Development Collaboration with Transcell Through Strategic Minority Investment

Patients for Patient Safety US to Celebrate Age-Friendly Hospital Measure on World Patient Safety Day

You may have missed